[
  {
    "objectID": "history.html",
    "href": "history.html",
    "title": "Change History",
    "section": "",
    "text": "Below is the history of detected changes for the monitored trials.\nNo history recorded yet.\nBack to Status Summary"
  },
  {
    "objectID": "history.html#historical-updates",
    "href": "history.html#historical-updates",
    "title": "Change History",
    "section": "",
    "text": "Below is the history of detected changes for the monitored trials.\nNo history recorded yet.\nBack to Status Summary"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Clinical Trial Watch",
    "section": "",
    "text": "This page monitors specific clinical trials and highlights any updates in their status or key fields.\nDownload Status Summary (CSV)\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT04818619\nAssiut University\nðŸŸ¢ No Change\nUNKNOWN\nChronic Myeloid Leukemia\nN/A\n2021-04\n2022-12\n65\n2021-03-25\n\n\nNCT04150965\nMultiple Myeloma Research Consortium\nðŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma, Relapsed Refractory Multiple Myeloma\nPHASE1, PHASE2\n2020-07-10\n2024-08-30\n14\n2025-02-12\n\n\nNCT05607563\nBiotheus Inc.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumor\nPHASE1\n2022-11-21\n2023-12\n54\n2023-02-07\n\n\nNCT05394168\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced/Metastatic Solid Tumors\nPHASE1\n2022-12-09\n2025-03-04\n12\n2024-03-28\n\n\nNCT07171307\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nConjunctivitis, Allergic\nN/A\n2026-01-01\n2026-09\n60\n2025-09-15\n\n\nNCT04995523\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-Small-Cell Lung Carcinoma\nPHASE1, PHASE2\n2021-09-14\n2028-03-16\n210\n2025-11-21\n\n\nNCT03119428\nOncoMed Pharmaceuticals, Inc.\nðŸŸ¢ No Change\nTERMINATED\nLocally Advanced Cancer, Metastatic Cancer\nPHASE1\n2017-05-02\n2019-05-15\n33\n2020-08-10\n\n\nNCT04500678\nUniversity of Hawaii\nðŸŸ¢ No Change\nUNKNOWN\nHIV/AIDS\nPHASE2, PHASE3\n2019-02-01\n2022-12-31\n38\n2020-08-04\n\n\nNCT05483400\nUniversity Medical Center Groningen\nðŸŸ¢ No Change\nRECRUITING\nHead and Neck Neoplasms, MSI-H Cancer, Melanoma\nPHASE2\n2023-10-18\n2027-09\n97\n2025-03-28\n\n\nNCT05390528\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors, Lymphoma, Metastatic Tumors\nPHASE1, PHASE2\n2022-06-20\n2024-12-30\n30\n2023-08-07\n\n\nNCT06250036\nRoyal Marsden NHS Foundation Trust\nðŸŸ¢ No Change\nRECRUITING\nLocally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer\nPHASE2\n2025-02-20\n2031-09-01\n50\n2025-08-19\n\n\nNCT05653284\nAkeso\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignant Tumors\nPHASE1\n2023-02-09\n2024-05-30\n19\n2024-08-11\n\n\nNCT05102214\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nUNKNOWN\nLocally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2022-05-03\n2024-02\n150\n2023-08-07\n\n\nNCT05023109\nShanghai Zhongshan Hospital\nðŸŸ¢ No Change\nUNKNOWN\nBiliary Tract Carcinoma\nPHASE2\n2021-02-01\n2024-12-01\n45\n2023-08-12\n\n\nNCT05130177\nDiwakar Davar\nðŸŸ¢ No Change\nRECRUITING\nMelanoma\nPHASE2\n2022-03-16\n2031-01\n26\n2025-05-02\n\n\nNCT04047862\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLocally Advanced and Metastatic Solid Tumors\nPHASE1\n2019-08-15\n2024-08-07\n446\n2025-08-04\n\n\nNCT05537051\nBiotheus Inc.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumours\nPHASE1\n2023-10-30\n2025-12-31\n30\n2023-02-07\n\n\nNCT05019677\nFudan University\nðŸŸ¢ No Change\nWITHDRAWN\nIntrahepatic Cholangiocarcinoma\nPHASE2\n2021-09-01\n2024-12-01\n0\n2022-03-22\n\n\nNCT05061628\nShanghai Junshi Bioscience Co., Ltd.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors\nPHASE1\n2021-04-21\n2024-09-30\n176\n2021-09-21\n\n\nNCT04656535\nYale University\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGlioblastoma\nEARLY_PHASE1\n2021-04-21\n2026-12-31\n46\n2026-01-06\n\n\nNCT06773507\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)\nPHASE1\n2025-05-12\n2027-06\n80\n2025-07-07\n\n\nNCT06349980\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Hepatocellular\nPHASE2\n2024-08-05\n2027-02-10\n117\n2024-12-15\n\n\nNCT05706207\nHuabo Biopharm Co., Ltd.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumor\nPHASE1\n2021-12-21\n2023-09-30\n36\n2023-01-20\n\n\nNCT05060432\niTeos Belgium SA\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma\nPHASE1, PHASE2\n2021-09-06\n2025-07\n153\n2024-06-19\n\n\nNCT06713798\nGustave Roussy, Cancer Campus, Grand Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nMetastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer\nPHASE2\n2025-07\n2030-01\n115\n2025-06-23\n\n\nNCT05394337\nM.D.Â Anderson Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nMetastatic Malignancy\nPHASE1, PHASE2\n2023-02-23\n2025-12-31\n10\n2025-10-07\n\n\nNCT05253105\nShanghai Junshi Bioscience Co., Ltd.\nðŸŸ¢ No Change\nWITHDRAWN\nPreviously Treated, Advanced, Malignancies\nPHASE1\n2022-03-15\n2027-01\n0\n2022-05-24\n\n\nNCT04270942\nProvention Bio, a Sanofi Company\nðŸŸ¢ No Change\nCOMPLETED\nDiabetes Mellitus, Type 1\nPHASE2\n2020-02-26\n2024-01-22\n6\n2025-01-20\n\n\nNCT05294952\nAssiut University\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nPre-Eclampsia\nPHASE4\n2025-01-01\n2025-11-04\n82\n2024-02-01\n\n\nNCT06754501\nM.D.Â Anderson Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nCancer\nPHASE2\n2025-04-11\n2029-07-01\n35\n2025-10-01\n\n\nNCT05757492\nCoherus Oncology, Inc.\nðŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma\nPHASE1\n2023-04-26\n2024-07-31\n22\n2025-04-30\n\n\nNCT04952597\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLimited Stage Small Cell Lung Cancer\nPHASE2\n2021-07-15\n2023-07-26\n126\n2024-10-23\n\n\nNCT05805501\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRenal Cell Carcinoma\nPHASE2\n2023-04-21\n2026-07-31\n199\n2025-11-12\n\n\nNCT03447678\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\nðŸŸ¢ No Change\nUNKNOWN\nNon Small Cell Lung Cancer (NSCLC)\nPHASE2\n2018-05-23\n2022-05-31\n65\n2021-06-08\n\n\nNCT04672369\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-06-06\n2023-06-01\n42\n2023-06-18\n\n\nNCT04672356\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-01-25\n2023-06-01\n19\n2023-06-18\n\n\nNCT05009069\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRectal Neoplasms, Rectal Cancer\nPHASE2\n2022-03-18\n2026-11-06\n58\n2026-01-16\n\n\nNCT04353830\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignancies\nPHASE1\n2020-05-22\n2022-05-11\n34\n2023-02-28\n\n\nNCT07337447\nHospices Civils de Lyon\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nCarcinoma, Neuroendocrine\nPHASE2\n2026-04\n2030-04\n122\n2026-01-07\n\n\nNCT04354246\nCompugen Ltd\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC\nPHASE1\n2020-03-31\n2025-12-30\n110\n2025-05-18\n\n\nNCT04933227\nHoffmann-La Roche\nðŸŸ¢ No Change\nTERMINATED\nStomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma\nPHASE2\n2021-08-06\n2023-11-17\n29\n2024-11-11\n\n\nNCT05414032\nUniversity Health Network, Toronto\nðŸŸ¢ No Change\nRECRUITING\nLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)\nPHASE2\n2023-07-12\n2026-07\n200\n2025-03-25\n\n\nNCT06003621\nOmico\nðŸŸ¢ No Change\nRECRUITING\nSolid Tumor, Adult\nPHASE2\n2023-12-15\n2028-11-01\n96\n2024-11-13\n\n\nNCT05568095\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Upper Gastrointestinal Tract Adenocarcinoma\nPHASE3\n2022-11-21\n2026-06\n1040\n2026-01-30\n\n\nNCT06777628\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\nðŸŸ¢ No Change\nRECRUITING\nLiver Cancer, Adult\nN/A\n2024-09-15\n2028-10-15\n100\n2025-01-14\n\n\nNCT06773481\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nGlioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM), Glioblastoma WHO Grade IV\nPHASE1\n2025-04-07\n2026-12\n40\n2025-07-07\n\n\nNCT03708224\nAlain Algazi\nðŸŸ¢ No Change\nRECRUITING\nCancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer\nPHASE2\n2019-03-08\n2028-06-30\n55\n2025-01-24\n\n\nNCT03652402\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nCOMPLETED\nKidney Transplant Rejection, Kidney Transplantation, Risk Stratification, Prognosis\nN/A\n2018-11-27\n2021-10-28\n558\n2024-06-04\n\n\nNCT03486119\nYonsei University\nðŸŸ¢ No Change\nCOMPLETED\nNon -Small Cell Lung Cancer\nN/A\n2018-02-05\n2020-07-07\n60\n2020-10-14\n\n\nNCT05120375\nBio-Thera Solutions\nðŸŸ¢ No Change\nTERMINATED\nSolid Tumor\nPHASE1\n2022-02-17\n2023-04-07\n5\n2023-10-08\n\n\nNCT05327530\nEMD Serono Research & Development Institute, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nLocally Advanced or Metastatic Urothelial Carcinoma\nPHASE2\n2022-08-17\n2026-06-25\n256\n2026-01-23\n\n\nNCT04570839\nCompugen Ltd\nðŸŸ¢ No Change\nCOMPLETED\nEndometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer\nPHASE1, PHASE2\n2020-08-31\n2024-05-15\n48\n2024-07-17\n\n\nNCT05520294\nUniversity of Colorado, Denver\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nN/A\n2022-09-01\n2024-08-31\n90\n2024-04-15\n\n\nNCT05417321\nShanghai Huaota Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumor, NSCLC\nPHASE1, PHASE2\n2022-08-25\n2025-08-01\n80\n2025-01-02\n\n\nNCT06328036\nNational Cancer Institute (NCI)\nðŸŸ¢ No Change\nWITHDRAWN\nRecurrent Glioblastoma, IDH-Wildtype\nPHASE2\n2025-04-30\n2025-07-01\n0\n2024-12-27\n\n\nNCT04465643\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\nðŸŸ¢ No Change\nCOMPLETED\nNerve Sheath Tumors\nPHASE1\n2021-06-08\n2025-07-30\n13\n2025-10-02\n\n\nNCT04262856\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2020-05-28\n2025-07-09\n151\n2025-08-25\n\n\nNCT04736173\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2021-02-08\n2027-05\n169\n2025-12-09\n\n\nNCT05126537\nSoutheast University, China\nðŸŸ¢ No Change\nUNKNOWN\n28 Day Mortality\nN/A\n2022-01-01\n2022-12-31\n100\n2022-11-25\n\n\nNCT05289492\niTeos Therapeutics\nðŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma\nPHASE1\n2022-05-01\n2023-11-29\n16\n2024-10-23\n\n\nNCT07115043\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma\nPHASE1, PHASE2\n2025-07-29\n2029-10-02\n60\n2025-12-18\n\n\nNCT05743504\nNational Taiwan University Hospital\nðŸŸ¢ No Change\nUNKNOWN\nLocally Advanced Esophageal Squamous Cell Carcinoma\nPHASE1, PHASE2\n2023-09-18\n2025-11-30\n32\n2024-01-31\n\n\nNCT05073484\nBio-Thera Solutions\nðŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor\nPHASE1\n2021-10-29\n2023-03-30\n13\n2023-10-09\n\n\nNCT07376512\nCentre Georges Francois Leclerc\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nNon-Small Cell Lung Cancer, Melanoma (Skin Cancer)\nN/A\n2026-03-01\n2030-03-01\n378\n2026-01-22\n\n\nNCT05904886\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nHepatocellular Carcinoma\nPHASE3\n2023-09-14\n2026-09-01\n687\n2025-12-30\n\n\nNCT03739710\nGlaxoSmithKline\nðŸŸ¢ No Change\nCOMPLETED\nNeoplasms\nPHASE2\n2019-01-24\n2024-05-02\n175\n2025-06-13\n\n\nNCT04791839\nWashington University School of Medicine\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer\nPHASE2\n2021-08-04\n2030-06-30\n30\n2025-11-04\n\n\nNCT05020912\nCase Comprehensive Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nBasal Cell Carcinoma\nPHASE2\n2021-12-13\n2027-12\n28\n2025-11-25\n\n\nNCT06334406\nCentre Hospitalier Universitaire de Besancon\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nBladder Cancer\nN/A\n2024-04-02\n2026-04-02\n33\n2024-03-19\n\n\nNCT07343310\nKine Sciences Co., Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nCIDP - Chronic Inflammatory Demyelinating Polyneuropathy\nPHASE1\n2024-08-27\n2025-04-14\n9\n2026-01-15\n\n\nNCT03342417\nExcellaBio LLC\nðŸŸ¢ No Change\nTERMINATED\nBreast Cancer Female, Ovarian Cancer, Gastric Cancer\nPHASE2\n2018-02-14\n2019-05-29\n5\n2021-11-05\n\n\nNCT04682665\nUniversity of Leeds\nðŸŸ¢ No Change\nCOMPLETED\nColon Cancer Liver Metastasis\nN/A\n2021-09-16\n2024-07-31\n81\n2024-12-03\n\n\nNCT05123482\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nBreast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer\nPHASE1, PHASE2\n2021-10-18\n2027-09-29\n460\n2025-12-02\n\n\nNCT07161414\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumors\nPHASE1\n2025-11-25\n2029-07-24\n40\n2025-12-18\n\n\nNCT07015164\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nHIV\nN/A\n2025-06-10\n2026-09-11\n80\n2025-06-03\n\n\nNCT05702229\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nGastric Cancer\nPHASE2\n2023-01-16\n2027-09-28\n240\n2025-11-14\n\n\nNCT07213882\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nEARLY_PHASE1\n2026-01-01\n2028-08-01\n30\n2025-10-02\n\n\nNCT03628677\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Unspecified, Adult\nPHASE1\n2018-09-12\n2025-01-23\n75\n2025-02-03\n\n\nNCT06897436\nMedical University of Lublin\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nEndometriosis\nN/A\n2025-05-01\n2029-12-31\n60\n2025-03-24\n\n\nNCT05633927\nHospitales Universitarios Virgen del RocÃ­o\nðŸŸ¢ No Change\nCOMPLETED\nSARS-CoV-2 RNA Vaccines, HIV Infection\nN/A\n2021-04-01\n2022-12-01\n48\n2024-10-09\n\n\nNCT04836507\nCurocell Inc.\nðŸŸ¢ No Change\nRECRUITING\nRelapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (TFL)\nPHASE1, PHASE2\n2021-03-02\n2028-02\n91\n2021-04-29\n\n\nNCT05775159\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Biliary Tract Cancer\nPHASE2\n2023-04-24\n2027-10-28\n294\n2025-11-12\n\n\nNCT06338657\nUniversity of Southern California\nðŸŸ¢ No Change\nTERMINATED\nHead and Neck Squamous Cell Carcinoma\nPHASE1\n2024-04-01\n2025-09-09\n1\n2025-09-09\n\n\nNCT06860815\nCity of Hope Medical Center\nðŸŸ¢ No Change\nRECRUITING\nAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver\nPHASE2\n2026-04-01\n2027-01-30\n11\n2026-01-27\n\n\nNCT04624828\nIstituto Clinico Humanitas\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nOligorecurrent and Oligoprogressive Prostate Cancer Patients\nNA\n2020-10-19\n2026-07\n40\n2025-04-22\n\n\nNCT05574335\nNational Institute of Allergy and Infectious Diseases (NIAID)\nðŸŸ¢ No Change\nTERMINATED\nType 1 Diabetes Mellitus\nPHASE1, PHASE2\n2023-04-26\n2025-10-20\n8\n2026-01-05\n\n\nNCT06302556\nFondazione IRCCS Caâ€™ Granda, Ospedale Maggiore Policlinico\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nLung Transplant Rejection\nN/A\n2024-04\n2026-02\n280\n2024-03-06\n\n\nNCT04761198\nMereo BioPharma\nðŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor\nPHASE1, PHASE2\n2021-03-23\n2023-10-30\n76\n2025-03-07\n\n\nNCT04693234\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nCervical Cancer\nPHASE2\n2021-02-15\n2023-08-31\n178\n2025-04-09\n\n\nNCT03563716\nGenentech, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nNon-small Cell Lung Cancer\nPHASE2\n2018-08-10\n2025-11-24\n135\n2025-12-30\n\n\nNCT07324642\nKine Sciences Co., Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nHealthy Volunteers\nPHASE1\n2025-05-26\n2025-08-25\n24\n2025-12-24\n\n\nNCT05809895\nNovartis Pharmaceuticals\nðŸŸ¢ No Change\nWITHDRAWN\nTriple Negative Breast Cancer\nPHASE2\n2023-09-15\n2029-07-18\n0\n2023-07-21\n\n\nNCT04732494\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nEsophageal Squamous Cell Carcinoma\nPHASE2\n2021-03-31\n2023-12-26\n125\n2024-12-23\n\n\nNCT05645692\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nUrothelial Cancer\nPHASE2\n2023-04-13\n2026-12-31\n204\n2026-01-28\n\n\nNCT04457778\nEMD Serono Research & Development Institute, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nMetastatic Solid Tumors\nPHASE1\n2020-07-10\n2023-06-23\n58\n2023-12-07\n\n\nNCT03772899\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.Â Josephâ€™s\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1\n2019-03-27\n2026-08\n20\n2025-03-26\n\n\nNCT04374877\nCoherus Oncology, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer\nPHASE1\n2020-04-22\n2025-06-05\n145\n2025-11-06\n\n\nNCT06346197\nCentre Leon Berard\nðŸŸ¢ No Change\nRECRUITING\nGastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer\nPHASE3\n2025-12-08\n2028-05-15\n132\n2025-12-19\n\n\nNCT05780073\nFundaciÃ³ Institut Germans Trias i Pujol\nðŸŸ¢ No Change\nCOMPLETED\nHIV Infection Primary\nPHASE2\n2023-10-16\n2025-04-01\n60\n2025-09-16\n\n\nNCT03667716\nCompugen Ltd\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer\nPHASE1\n2018-09-06\n2024-01-30\n121\n2025-01-15\n\n\nNCT06784947\nUniversity of Colorado, Denver\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMicrosatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV\nPHASE2\n2025-03-25\n2028-05\n13\n2025-10-01\n\n\nNCT05014815\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV\nPHASE2\n2021-11-16\n2024-09-04\n272\n2025-08-28\n\n\nNCT07307053\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nRare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors\nPHASE1, PHASE2\n2026-01-01\n2031-01-31\n600\n2025-12-13\n\n\nNCT04746924\nBeiGene\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon-small Cell Lung Cancer, NSCLC\nPHASE3\n2021-06-08\n2026-03-31\n662\n2025-06-23\n\n\nNCT07098338\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-Small Cell Lung Cancer\nPHASE2\n2025-08-07\n2029-04-06\n278\n2025-09-25\n\n\nNCT06532539\nShandong Cancer Hospital and Institute\nðŸŸ¢ No Change\nRECRUITING\nEndometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis\nPHASE2\n2024-06-13\n2026-05\n30\n2024-07-29\n\n\nNCT06864598\nPeking University Peopleâ€™s Hospital\nðŸŸ¢ No Change\nENROLLING_BY_INVITATION\nGraft-versus-host Disease (GVHD)\nN/A\n2025-01-09\n2026-10-31\n100\n2025-03-04\n\n\nNCT03661047\nMassachusetts General Hospital\nðŸŸ¢ No Change\nWITHDRAWN\nColon Cancer\nPHASE2\n2019-11-30\n2021-11-30\n0\n2021-11-10\n\n\nNCT04866017\nBeiGene\nðŸŸ¢ No Change\nTERMINATED\nNon Small Cell Lung Cancer\nPHASE3\n2021-06-17\n2023-10-17\n63\n2024-10-09\n\n\nNCT05127824\nJodi Maranchie\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Renal Cell\nPHASE2\n2023-07-06\n2026-12\n42\n2025-04-30\n\n\nNCT04303169\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-09-24\n146\n2025-10-23\n\n\nNCT05329766\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGastrointestinal Tract Malignancies\nPHASE2\n2022-06-10\n2027-06\n332\n2026-01-27\n\n\nNCT04323202\nCase Comprehensive Cancer Center\nðŸŸ¢ No Change\nCOMPLETED\nBasal Cell Carcinoma of the Head and Neck\nPHASE1\n2020-08-04\n2025-06-25\n13\n2025-10-23\n\n\nNCT07221253\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nBiliary Tract Cancer\nPHASE3\n2025-12-04\n2029-07-04\n1100\n2026-01-07\n\n\nNCT05676931\nGilead Sciences\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Non-Small Cell Lung Cancer\nPHASE2\n2023-02-21\n2027-12\n400\n2025-09-29\n\n\nNCT06790706\nHospices Civils de Lyon\nðŸŸ¢ No Change\nRECRUITING\nPeritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid Tumor\nPHASE2\n2025-10-01\n2031-06\n154\n2025-10-01\n\n\nNCT04543617\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nEsophageal Squamous Cell Carcinoma\nPHASE3\n2020-09-28\n2027-03-31\n760\n2026-01-16\n\n\nNCT04305041\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-08-25\n100\n2025-08-28\n\n\nNCT06996782\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nAdvanced or Metastatic Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2025-11-24\n2029-02-23\n152\n2026-01-13\n\n\nNCT05665595\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE3\n2023-01-19\n2025-09-26\n1594\n2025-10-03\n\n\nNCT06868277\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Non-Small Cell Lung\nPHASE3\n2025-04-10\n2030-12-02\n830\n2026-01-12\n\n\nNCT06692738\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-small Cell Lung Cancer\nPHASE3\n2024-11-18\n2029-10-08\n880\n2026-01-20\n\n\nNCT04774484\nFrancesc Marti\nðŸŸ¢ No Change\nWITHDRAWN\nEnd Stage Renal Disease\nNA\n2023-01\n2026-06-30\n0\n2023-02-10\n\n\nNCT04256421\nHoffmann-La Roche\nðŸŸ¢ No Change\nCOMPLETED\nSmall Cell Lung Cancer\nPHASE3\n2020-02-04\n2025-07-31\n490\n2026-01-09\n\n\nNCT06989112\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nEndometrial Cancer\nPHASE3\n2025-03-27\n2031-02-19\n600\n2026-01-14\n\n\nNCT05816460\nUniversity College Dublin\nðŸŸ¢ No Change\nUNKNOWN\nInsomnia, Cancer\nNA\n2023-05-22\n2024-06-10\n308\n2023-05-19\n\n\nNCT06627647\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-squamous Non-small Cell Lung Cancer\nPHASE3\n2024-11-27\n2030-03-25\n878\n2025-12-19\n\n\nNCT04305054\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1, PHASE2\n2020-07-01\n2026-04-20\n315\n2025-08-28\n\n\nNCT04294810\nHoffmann-La Roche\nðŸŸ¢ No Change\nCOMPLETED\nNon-Small Cell Lung Cancer\nPHASE3\n2020-03-04\n2025-12-30\n620\n2026-01-29\n\n\nNCT03198546\nSecond Affiliated Hospital of Guangzhou Medical University\nðŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Cancer\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT03198052\nSecond Affiliated Hospital of Guangzhou Medical University\nðŸŸ¢ No Change\nRECRUITING\nLung Cancer, Cancer, Immunotherapy, CAR-T Cell\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT04585815\nPfizer\nðŸŸ¢ No Change\nTERMINATED\nCarcinoma, Non-Small-Cell Lung\nPHASE1, PHASE2\n2020-11-10\n2024-10-29\n34\n2025-12-18\n\n\nNCT02443155\nNovo Nordisk A/S\nðŸŸ¢ No Change\nCOMPLETED\nDiabetes, Diabetes Mellitus, Type 1\nPHASE2\n2015-11-10\n2019-02-27\n308\n2021-03-10\n\n\n\nView Full Change History"
  },
  {
    "objectID": "index.html#monitoring-status",
    "href": "index.html#monitoring-status",
    "title": "Clinical Trial Watch",
    "section": "",
    "text": "This page monitors specific clinical trials and highlights any updates in their status or key fields.\nDownload Status Summary (CSV)\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT04818619\nAssiut University\nðŸŸ¢ No Change\nUNKNOWN\nChronic Myeloid Leukemia\nN/A\n2021-04\n2022-12\n65\n2021-03-25\n\n\nNCT04150965\nMultiple Myeloma Research Consortium\nðŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma, Relapsed Refractory Multiple Myeloma\nPHASE1, PHASE2\n2020-07-10\n2024-08-30\n14\n2025-02-12\n\n\nNCT05607563\nBiotheus Inc.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumor\nPHASE1\n2022-11-21\n2023-12\n54\n2023-02-07\n\n\nNCT05394168\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced/Metastatic Solid Tumors\nPHASE1\n2022-12-09\n2025-03-04\n12\n2024-03-28\n\n\nNCT07171307\nInstituto de OftalmologÃ­a FundaciÃ³n Conde de Valenciana\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nConjunctivitis, Allergic\nN/A\n2026-01-01\n2026-09\n60\n2025-09-15\n\n\nNCT04995523\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-Small-Cell Lung Carcinoma\nPHASE1, PHASE2\n2021-09-14\n2028-03-16\n210\n2025-11-21\n\n\nNCT03119428\nOncoMed Pharmaceuticals, Inc.\nðŸŸ¢ No Change\nTERMINATED\nLocally Advanced Cancer, Metastatic Cancer\nPHASE1\n2017-05-02\n2019-05-15\n33\n2020-08-10\n\n\nNCT04500678\nUniversity of Hawaii\nðŸŸ¢ No Change\nUNKNOWN\nHIV/AIDS\nPHASE2, PHASE3\n2019-02-01\n2022-12-31\n38\n2020-08-04\n\n\nNCT05483400\nUniversity Medical Center Groningen\nðŸŸ¢ No Change\nRECRUITING\nHead and Neck Neoplasms, MSI-H Cancer, Melanoma\nPHASE2\n2023-10-18\n2027-09\n97\n2025-03-28\n\n\nNCT05390528\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors, Lymphoma, Metastatic Tumors\nPHASE1, PHASE2\n2022-06-20\n2024-12-30\n30\n2023-08-07\n\n\nNCT06250036\nRoyal Marsden NHS Foundation Trust\nðŸŸ¢ No Change\nRECRUITING\nLocally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer\nPHASE2\n2025-02-20\n2031-09-01\n50\n2025-08-19\n\n\nNCT05653284\nAkeso\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignant Tumors\nPHASE1\n2023-02-09\n2024-05-30\n19\n2024-08-11\n\n\nNCT05102214\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nUNKNOWN\nLocally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2022-05-03\n2024-02\n150\n2023-08-07\n\n\nNCT05023109\nShanghai Zhongshan Hospital\nðŸŸ¢ No Change\nUNKNOWN\nBiliary Tract Carcinoma\nPHASE2\n2021-02-01\n2024-12-01\n45\n2023-08-12\n\n\nNCT05130177\nDiwakar Davar\nðŸŸ¢ No Change\nRECRUITING\nMelanoma\nPHASE2\n2022-03-16\n2031-01\n26\n2025-05-02\n\n\nNCT04047862\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLocally Advanced and Metastatic Solid Tumors\nPHASE1\n2019-08-15\n2024-08-07\n446\n2025-08-04\n\n\nNCT05537051\nBiotheus Inc.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumours\nPHASE1\n2023-10-30\n2025-12-31\n30\n2023-02-07\n\n\nNCT05019677\nFudan University\nðŸŸ¢ No Change\nWITHDRAWN\nIntrahepatic Cholangiocarcinoma\nPHASE2\n2021-09-01\n2024-12-01\n0\n2022-03-22\n\n\nNCT05061628\nShanghai Junshi Bioscience Co., Ltd.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Tumors\nPHASE1\n2021-04-21\n2024-09-30\n176\n2021-09-21\n\n\nNCT04656535\nYale University\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGlioblastoma\nEARLY_PHASE1\n2021-04-21\n2026-12-31\n46\n2026-01-06\n\n\nNCT06773507\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)\nPHASE1\n2025-05-12\n2027-06\n80\n2025-07-07\n\n\nNCT06349980\nShanghai Henlius Biotech\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Hepatocellular\nPHASE2\n2024-08-05\n2027-02-10\n117\n2024-12-15\n\n\nNCT05706207\nHuabo Biopharm Co., Ltd.\nðŸŸ¢ No Change\nUNKNOWN\nAdvanced Solid Tumor\nPHASE1\n2021-12-21\n2023-09-30\n36\n2023-01-20\n\n\nNCT05060432\niTeos Belgium SA\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma\nPHASE1, PHASE2\n2021-09-06\n2025-07\n153\n2024-06-19\n\n\nNCT06713798\nGustave Roussy, Cancer Campus, Grand Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nMetastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer\nPHASE2\n2025-07\n2030-01\n115\n2025-06-23\n\n\nNCT05394337\nM.D.Â Anderson Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nMetastatic Malignancy\nPHASE1, PHASE2\n2023-02-23\n2025-12-31\n10\n2025-10-07\n\n\nNCT05253105\nShanghai Junshi Bioscience Co., Ltd.\nðŸŸ¢ No Change\nWITHDRAWN\nPreviously Treated, Advanced, Malignancies\nPHASE1\n2022-03-15\n2027-01\n0\n2022-05-24\n\n\nNCT04270942\nProvention Bio, a Sanofi Company\nðŸŸ¢ No Change\nCOMPLETED\nDiabetes Mellitus, Type 1\nPHASE2\n2020-02-26\n2024-01-22\n6\n2025-01-20\n\n\nNCT05294952\nAssiut University\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nPre-Eclampsia\nPHASE4\n2025-01-01\n2025-11-04\n82\n2024-02-01\n\n\nNCT06754501\nM.D.Â Anderson Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nCancer\nPHASE2\n2025-04-11\n2029-07-01\n35\n2025-10-01\n\n\nNCT05757492\nCoherus Oncology, Inc.\nðŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma\nPHASE1\n2023-04-26\n2024-07-31\n22\n2025-04-30\n\n\nNCT04952597\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLimited Stage Small Cell Lung Cancer\nPHASE2\n2021-07-15\n2023-07-26\n126\n2024-10-23\n\n\nNCT05805501\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRenal Cell Carcinoma\nPHASE2\n2023-04-21\n2026-07-31\n199\n2025-11-12\n\n\nNCT03447678\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\nðŸŸ¢ No Change\nUNKNOWN\nNon Small Cell Lung Cancer (NSCLC)\nPHASE2\n2018-05-23\n2022-05-31\n65\n2021-06-08\n\n\nNCT04672369\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-06-06\n2023-06-01\n42\n2023-06-18\n\n\nNCT04672356\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-01-25\n2023-06-01\n19\n2023-06-18\n\n\nNCT05009069\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nRectal Neoplasms, Rectal Cancer\nPHASE2\n2022-03-18\n2026-11-06\n58\n2026-01-16\n\n\nNCT04353830\nInnovent Biologics (Suzhou) Co.Â Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Malignancies\nPHASE1\n2020-05-22\n2022-05-11\n34\n2023-02-28\n\n\nNCT07337447\nHospices Civils de Lyon\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nCarcinoma, Neuroendocrine\nPHASE2\n2026-04\n2030-04\n122\n2026-01-07\n\n\nNCT04354246\nCompugen Ltd\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC\nPHASE1\n2020-03-31\n2025-12-30\n110\n2025-05-18\n\n\nNCT04933227\nHoffmann-La Roche\nðŸŸ¢ No Change\nTERMINATED\nStomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma\nPHASE2\n2021-08-06\n2023-11-17\n29\n2024-11-11\n\n\nNCT05414032\nUniversity Health Network, Toronto\nðŸŸ¢ No Change\nRECRUITING\nLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)\nPHASE2\n2023-07-12\n2026-07\n200\n2025-03-25\n\n\nNCT06003621\nOmico\nðŸŸ¢ No Change\nRECRUITING\nSolid Tumor, Adult\nPHASE2\n2023-12-15\n2028-11-01\n96\n2024-11-13\n\n\nNCT05568095\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Upper Gastrointestinal Tract Adenocarcinoma\nPHASE3\n2022-11-21\n2026-06\n1040\n2026-01-30\n\n\nNCT06777628\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\nðŸŸ¢ No Change\nRECRUITING\nLiver Cancer, Adult\nN/A\n2024-09-15\n2028-10-15\n100\n2025-01-14\n\n\nNCT06773481\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nGlioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM), Glioblastoma WHO Grade IV\nPHASE1\n2025-04-07\n2026-12\n40\n2025-07-07\n\n\nNCT03708224\nAlain Algazi\nðŸŸ¢ No Change\nRECRUITING\nCancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer\nPHASE2\n2019-03-08\n2028-06-30\n55\n2025-01-24\n\n\nNCT03652402\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nCOMPLETED\nKidney Transplant Rejection, Kidney Transplantation, Risk Stratification, Prognosis\nN/A\n2018-11-27\n2021-10-28\n558\n2024-06-04\n\n\nNCT03486119\nYonsei University\nðŸŸ¢ No Change\nCOMPLETED\nNon -Small Cell Lung Cancer\nN/A\n2018-02-05\n2020-07-07\n60\n2020-10-14\n\n\nNCT05120375\nBio-Thera Solutions\nðŸŸ¢ No Change\nTERMINATED\nSolid Tumor\nPHASE1\n2022-02-17\n2023-04-07\n5\n2023-10-08\n\n\nNCT05327530\nEMD Serono Research & Development Institute, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nLocally Advanced or Metastatic Urothelial Carcinoma\nPHASE2\n2022-08-17\n2026-06-25\n256\n2026-01-23\n\n\nNCT04570839\nCompugen Ltd\nðŸŸ¢ No Change\nCOMPLETED\nEndometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer\nPHASE1, PHASE2\n2020-08-31\n2024-05-15\n48\n2024-07-17\n\n\nNCT05520294\nUniversity of Colorado, Denver\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nN/A\n2022-09-01\n2024-08-31\n90\n2024-04-15\n\n\nNCT05417321\nShanghai Huaota Biopharmaceutical Co., Ltd.\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumor, NSCLC\nPHASE1, PHASE2\n2022-08-25\n2025-08-01\n80\n2025-01-02\n\n\nNCT06328036\nNational Cancer Institute (NCI)\nðŸŸ¢ No Change\nWITHDRAWN\nRecurrent Glioblastoma, IDH-Wildtype\nPHASE2\n2025-04-30\n2025-07-01\n0\n2024-12-27\n\n\nNCT04465643\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\nðŸŸ¢ No Change\nCOMPLETED\nNerve Sheath Tumors\nPHASE1\n2021-06-08\n2025-07-30\n13\n2025-10-02\n\n\nNCT04262856\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2020-05-28\n2025-07-09\n151\n2025-08-25\n\n\nNCT04736173\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2021-02-08\n2027-05\n169\n2025-12-09\n\n\nNCT05126537\nSoutheast University, China\nðŸŸ¢ No Change\nUNKNOWN\n28 Day Mortality\nN/A\n2022-01-01\n2022-12-31\n100\n2022-11-25\n\n\nNCT05289492\niTeos Therapeutics\nðŸŸ¢ No Change\nTERMINATED\nMultiple Myeloma\nPHASE1\n2022-05-01\n2023-11-29\n16\n2024-10-23\n\n\nNCT07115043\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma\nPHASE1, PHASE2\n2025-07-29\n2029-10-02\n60\n2025-12-18\n\n\nNCT05743504\nNational Taiwan University Hospital\nðŸŸ¢ No Change\nUNKNOWN\nLocally Advanced Esophageal Squamous Cell Carcinoma\nPHASE1, PHASE2\n2023-09-18\n2025-11-30\n32\n2024-01-31\n\n\nNCT05073484\nBio-Thera Solutions\nðŸŸ¢ No Change\nTERMINATED\nAdvanced Solid Tumor\nPHASE1\n2021-10-29\n2023-03-30\n13\n2023-10-09\n\n\nNCT07376512\nCentre Georges Francois Leclerc\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nNon-Small Cell Lung Cancer, Melanoma (Skin Cancer)\nN/A\n2026-03-01\n2030-03-01\n378\n2026-01-22\n\n\nNCT05904886\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nHepatocellular Carcinoma\nPHASE3\n2023-09-14\n2026-09-01\n687\n2025-12-30\n\n\nNCT03739710\nGlaxoSmithKline\nðŸŸ¢ No Change\nCOMPLETED\nNeoplasms\nPHASE2\n2019-01-24\n2024-05-02\n175\n2025-06-13\n\n\nNCT04791839\nWashington University School of Medicine\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer\nPHASE2\n2021-08-04\n2030-06-30\n30\n2025-11-04\n\n\nNCT05020912\nCase Comprehensive Cancer Center\nðŸŸ¢ No Change\nRECRUITING\nBasal Cell Carcinoma\nPHASE2\n2021-12-13\n2027-12\n28\n2025-11-25\n\n\nNCT06334406\nCentre Hospitalier Universitaire de Besancon\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nBladder Cancer\nN/A\n2024-04-02\n2026-04-02\n33\n2024-03-19\n\n\nNCT07343310\nKine Sciences Co., Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nCIDP - Chronic Inflammatory Demyelinating Polyneuropathy\nPHASE1\n2024-08-27\n2025-04-14\n9\n2026-01-15\n\n\nNCT03342417\nExcellaBio LLC\nðŸŸ¢ No Change\nTERMINATED\nBreast Cancer Female, Ovarian Cancer, Gastric Cancer\nPHASE2\n2018-02-14\n2019-05-29\n5\n2021-11-05\n\n\nNCT04682665\nUniversity of Leeds\nðŸŸ¢ No Change\nCOMPLETED\nColon Cancer Liver Metastasis\nN/A\n2021-09-16\n2024-07-31\n81\n2024-12-03\n\n\nNCT05123482\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nBreast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer\nPHASE1, PHASE2\n2021-10-18\n2027-09-29\n460\n2025-12-02\n\n\nNCT07161414\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nAdvanced Solid Tumors\nPHASE1\n2025-11-25\n2029-07-24\n40\n2025-12-18\n\n\nNCT07015164\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nHIV\nN/A\n2025-06-10\n2026-09-11\n80\n2025-06-03\n\n\nNCT05702229\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nGastric Cancer\nPHASE2\n2023-01-16\n2027-09-28\n240\n2025-11-14\n\n\nNCT07213882\nAssistance Publique - HÃ´pitaux de Paris\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nEARLY_PHASE1\n2026-01-01\n2028-08-01\n30\n2025-10-02\n\n\nNCT03628677\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Unspecified, Adult\nPHASE1\n2018-09-12\n2025-01-23\n75\n2025-02-03\n\n\nNCT06897436\nMedical University of Lublin\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nEndometriosis\nN/A\n2025-05-01\n2029-12-31\n60\n2025-03-24\n\n\nNCT05633927\nHospitales Universitarios Virgen del RocÃ­o\nðŸŸ¢ No Change\nCOMPLETED\nSARS-CoV-2 RNA Vaccines, HIV Infection\nN/A\n2021-04-01\n2022-12-01\n48\n2024-10-09\n\n\nNCT04836507\nCurocell Inc.\nðŸŸ¢ No Change\nRECRUITING\nRelapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (TFL)\nPHASE1, PHASE2\n2021-03-02\n2028-02\n91\n2021-04-29\n\n\nNCT05775159\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Biliary Tract Cancer\nPHASE2\n2023-04-24\n2027-10-28\n294\n2025-11-12\n\n\nNCT06338657\nUniversity of Southern California\nðŸŸ¢ No Change\nTERMINATED\nHead and Neck Squamous Cell Carcinoma\nPHASE1\n2024-04-01\n2025-09-09\n1\n2025-09-09\n\n\nNCT06860815\nCity of Hope Medical Center\nðŸŸ¢ No Change\nRECRUITING\nAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver\nPHASE2\n2026-04-01\n2027-01-30\n11\n2026-01-27\n\n\nNCT04624828\nIstituto Clinico Humanitas\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nOligorecurrent and Oligoprogressive Prostate Cancer Patients\nNA\n2020-10-19\n2026-07\n40\n2025-04-22\n\n\nNCT05574335\nNational Institute of Allergy and Infectious Diseases (NIAID)\nðŸŸ¢ No Change\nTERMINATED\nType 1 Diabetes Mellitus\nPHASE1, PHASE2\n2023-04-26\n2025-10-20\n8\n2026-01-05\n\n\nNCT06302556\nFondazione IRCCS Caâ€™ Granda, Ospedale Maggiore Policlinico\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nLung Transplant Rejection\nN/A\n2024-04\n2026-02\n280\n2024-03-06\n\n\nNCT04761198\nMereo BioPharma\nðŸŸ¢ No Change\nCOMPLETED\nSolid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor\nPHASE1, PHASE2\n2021-03-23\n2023-10-30\n76\n2025-03-07\n\n\nNCT04693234\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nCervical Cancer\nPHASE2\n2021-02-15\n2023-08-31\n178\n2025-04-09\n\n\nNCT03563716\nGenentech, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nNon-small Cell Lung Cancer\nPHASE2\n2018-08-10\n2025-11-24\n135\n2025-12-30\n\n\nNCT07324642\nKine Sciences Co., Ltd.\nðŸŸ¢ No Change\nCOMPLETED\nHealthy Volunteers\nPHASE1\n2025-05-26\n2025-08-25\n24\n2025-12-24\n\n\nNCT05809895\nNovartis Pharmaceuticals\nðŸŸ¢ No Change\nWITHDRAWN\nTriple Negative Breast Cancer\nPHASE2\n2023-09-15\n2029-07-18\n0\n2023-07-21\n\n\nNCT04732494\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nEsophageal Squamous Cell Carcinoma\nPHASE2\n2021-03-31\n2023-12-26\n125\n2024-12-23\n\n\nNCT05645692\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nUrothelial Cancer\nPHASE2\n2023-04-13\n2026-12-31\n204\n2026-01-28\n\n\nNCT04457778\nEMD Serono Research & Development Institute, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nMetastatic Solid Tumors\nPHASE1\n2020-07-10\n2023-06-23\n58\n2023-12-07\n\n\nNCT03772899\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.Â Josephâ€™s\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1\n2019-03-27\n2026-08\n20\n2025-03-26\n\n\nNCT04374877\nCoherus Oncology, Inc.\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer\nPHASE1\n2020-04-22\n2025-06-05\n145\n2025-11-06\n\n\nNCT06346197\nCentre Leon Berard\nðŸŸ¢ No Change\nRECRUITING\nGastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer\nPHASE3\n2025-12-08\n2028-05-15\n132\n2025-12-19\n\n\nNCT05780073\nFundaciÃ³ Institut Germans Trias i Pujol\nðŸŸ¢ No Change\nCOMPLETED\nHIV Infection Primary\nPHASE2\n2023-10-16\n2025-04-01\n60\n2025-09-16\n\n\nNCT03667716\nCompugen Ltd\nðŸŸ¢ No Change\nCOMPLETED\nAdvanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer\nPHASE1\n2018-09-06\n2024-01-30\n121\n2025-01-15\n\n\nNCT06784947\nUniversity of Colorado, Denver\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMicrosatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV\nPHASE2\n2025-03-25\n2028-05\n13\n2025-10-01\n\n\nNCT05014815\nBeiGene\nðŸŸ¢ No Change\nCOMPLETED\nLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV\nPHASE2\n2021-11-16\n2024-09-04\n272\n2025-08-28\n\n\nNCT07307053\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\nðŸŸ¢ No Change\nNOT_YET_RECRUITING\nRare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors\nPHASE1, PHASE2\n2026-01-01\n2031-01-31\n600\n2025-12-13\n\n\nNCT04746924\nBeiGene\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nNon-small Cell Lung Cancer, NSCLC\nPHASE3\n2021-06-08\n2026-03-31\n662\n2025-06-23\n\n\nNCT07098338\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-Small Cell Lung Cancer\nPHASE2\n2025-08-07\n2029-04-06\n278\n2025-09-25\n\n\nNCT06532539\nShandong Cancer Hospital and Institute\nðŸŸ¢ No Change\nRECRUITING\nEndometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis\nPHASE2\n2024-06-13\n2026-05\n30\n2024-07-29\n\n\nNCT06864598\nPeking University Peopleâ€™s Hospital\nðŸŸ¢ No Change\nENROLLING_BY_INVITATION\nGraft-versus-host Disease (GVHD)\nN/A\n2025-01-09\n2026-10-31\n100\n2025-03-04\n\n\nNCT03661047\nMassachusetts General Hospital\nðŸŸ¢ No Change\nWITHDRAWN\nColon Cancer\nPHASE2\n2019-11-30\n2021-11-30\n0\n2021-11-10\n\n\nNCT04866017\nBeiGene\nðŸŸ¢ No Change\nTERMINATED\nNon Small Cell Lung Cancer\nPHASE3\n2021-06-17\n2023-10-17\n63\n2024-10-09\n\n\nNCT05127824\nJodi Maranchie\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Renal Cell\nPHASE2\n2023-07-06\n2026-12\n42\n2025-04-30\n\n\nNCT04303169\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-09-24\n146\n2025-10-23\n\n\nNCT05329766\nArcus Biosciences, Inc.\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nGastrointestinal Tract Malignancies\nPHASE2\n2022-06-10\n2027-06\n332\n2026-01-27\n\n\nNCT04323202\nCase Comprehensive Cancer Center\nðŸŸ¢ No Change\nCOMPLETED\nBasal Cell Carcinoma of the Head and Neck\nPHASE1\n2020-08-04\n2025-06-25\n13\n2025-10-23\n\n\nNCT07221253\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nBiliary Tract Cancer\nPHASE3\n2025-12-04\n2029-07-04\n1100\n2026-01-07\n\n\nNCT05676931\nGilead Sciences\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Non-Small Cell Lung Cancer\nPHASE2\n2023-02-21\n2027-12\n400\n2025-09-29\n\n\nNCT06790706\nHospices Civils de Lyon\nðŸŸ¢ No Change\nRECRUITING\nPeritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid Tumor\nPHASE2\n2025-10-01\n2031-06\n154\n2025-10-01\n\n\nNCT04543617\nHoffmann-La Roche\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nEsophageal Squamous Cell Carcinoma\nPHASE3\n2020-09-28\n2027-03-31\n760\n2026-01-16\n\n\nNCT04305041\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-08-25\n100\n2025-08-28\n\n\nNCT06996782\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nAdvanced or Metastatic Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2025-11-24\n2029-02-23\n152\n2026-01-13\n\n\nNCT05665595\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nCOMPLETED\nMelanoma\nPHASE3\n2023-01-19\n2025-09-26\n1594\n2025-10-03\n\n\nNCT06868277\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nCarcinoma, Non-Small Cell Lung\nPHASE3\n2025-04-10\n2030-12-02\n830\n2026-01-12\n\n\nNCT06692738\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-small Cell Lung Cancer\nPHASE3\n2024-11-18\n2029-10-08\n880\n2026-01-20\n\n\nNCT04774484\nFrancesc Marti\nðŸŸ¢ No Change\nWITHDRAWN\nEnd Stage Renal Disease\nNA\n2023-01\n2026-06-30\n0\n2023-02-10\n\n\nNCT04256421\nHoffmann-La Roche\nðŸŸ¢ No Change\nCOMPLETED\nSmall Cell Lung Cancer\nPHASE3\n2020-02-04\n2025-07-31\n490\n2026-01-09\n\n\nNCT06989112\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nEndometrial Cancer\nPHASE3\n2025-03-27\n2031-02-19\n600\n2026-01-14\n\n\nNCT05816460\nUniversity College Dublin\nðŸŸ¢ No Change\nUNKNOWN\nInsomnia, Cancer\nNA\n2023-05-22\n2024-06-10\n308\n2023-05-19\n\n\nNCT06627647\nAstraZeneca\nðŸŸ¢ No Change\nRECRUITING\nNon-squamous Non-small Cell Lung Cancer\nPHASE3\n2024-11-27\n2030-03-25\n878\n2025-12-19\n\n\nNCT04305054\nMerck Sharp & Dohme LLC\nðŸŸ¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1, PHASE2\n2020-07-01\n2026-04-20\n315\n2025-08-28\n\n\nNCT04294810\nHoffmann-La Roche\nðŸŸ¢ No Change\nCOMPLETED\nNon-Small Cell Lung Cancer\nPHASE3\n2020-03-04\n2025-12-30\n620\n2026-01-29\n\n\nNCT03198546\nSecond Affiliated Hospital of Guangzhou Medical University\nðŸŸ¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Cancer\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT03198052\nSecond Affiliated Hospital of Guangzhou Medical University\nðŸŸ¢ No Change\nRECRUITING\nLung Cancer, Cancer, Immunotherapy, CAR-T Cell\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT04585815\nPfizer\nðŸŸ¢ No Change\nTERMINATED\nCarcinoma, Non-Small-Cell Lung\nPHASE1, PHASE2\n2020-11-10\n2024-10-29\n34\n2025-12-18\n\n\nNCT02443155\nNovo Nordisk A/S\nðŸŸ¢ No Change\nCOMPLETED\nDiabetes, Diabetes Mellitus, Type 1\nPHASE2\n2015-11-10\n2019-02-27\n308\n2021-03-10\n\n\n\nView Full Change History"
  },
  {
    "objectID": "full_data.html",
    "href": "full_data.html",
    "title": "Data Insights",
    "section": "",
    "text": "This page provides a visual overview of the clinical trials being monitored. The visualizations are based on the latest consolidated raw data.\nDownload Full Snapshots (CSV)\n\nStatus & PhaseTimelineTop Sponsors\n\n\n\n\n                            \n                                            \n\n\n\n\n                            \n                                            \n\n\n\n\n\n\n                            \n                                            \n\n\n\n\n\n\n                            \n                                            \n\n\n\n\n\nBack to Status Summary"
  },
  {
    "objectID": "full_data.html#visual-summary-of-all-monitored-trials",
    "href": "full_data.html#visual-summary-of-all-monitored-trials",
    "title": "Data Insights",
    "section": "",
    "text": "This page provides a visual overview of the clinical trials being monitored. The visualizations are based on the latest consolidated raw data.\nDownload Full Snapshots (CSV)\n\nStatus & PhaseTimelineTop Sponsors\n\n\n\n\n                            \n                                            \n\n\n\n\n                            \n                                            \n\n\n\n\n\n\n                            \n                                            \n\n\n\n\n\n\n                            \n                                            \n\n\n\n\n\nBack to Status Summary"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "Clinical Trial Watch (TIGIT) is an automated monitoring system designed to track changes in clinical trials related to TIGIT-targeted therapies. By leveraging the ClinicalTrials.gov API v2, this project provides researchers and clinicians with a clear, up-to-date view of the TIGIT landscape."
  },
  {
    "objectID": "about.html#project-overview",
    "href": "about.html#project-overview",
    "title": "About",
    "section": "",
    "text": "Clinical Trial Watch (TIGIT) is an automated monitoring system designed to track changes in clinical trials related to TIGIT-targeted therapies. By leveraging the ClinicalTrials.gov API v2, this project provides researchers and clinicians with a clear, up-to-date view of the TIGIT landscape."
  },
  {
    "objectID": "about.html#key-features",
    "href": "about.html#key-features",
    "title": "About",
    "section": "Key Features",
    "text": "Key Features\n\nAutomated Monitoring: Daily updates on the status and key parameters of TIGIT-related clinical trials.\nChange Detection: Intelligent diffing engine that highlights meaningful changes in recruitment status, phase, and completion dates.\nData Insights: Interactive visualizations to help understand clinical trial trends and distributions.\nOpen Data: All consolidated raw data is available for download as a CSV for deeper analysis."
  },
  {
    "objectID": "about.html#how-it-works",
    "href": "about.html#how-it-works",
    "title": "About",
    "section": "How it Works",
    "text": "How it Works\n\nDaily Watch: A GitHub Actions workflow runs every 24 hours to fetch the latest data for all NCT IDs listed in trials.yaml.\nAnalysis: The src/main.py script compares current data with previous snapshots to identify any changes.\nReport Generation: Updates are logged in the history.qmd page, and the dashboard is refreshed with the latest summary stats.\nPublishing: The updated Quarto website is automatically published to GitHub Pages."
  },
  {
    "objectID": "about.html#data-source",
    "href": "about.html#data-source",
    "title": "About",
    "section": "Data Source",
    "text": "Data Source\nAll data is sourced from ClinicalTrials.gov via their official API.\n\nThis project is built using Python, Quarto, and GitHub Actions."
  }
]